Health Care International - Ipsogen Announces 3 Studies At ASCO Meeting Extending The Utility Of The Genomic Grade Index For Predicting Response To Chemotherapy In Breast Cancer
IPSOGEN SA (Marseille and New Haven), a cancer profiler that develops and markets molecular diagnostic assays for blood & breast cancers, announced that researchers from the University of Texas MD Anderson Cancer Center (MDACC, Houston, TX) will pre
Comments